Introduction. Hereditary tyrosinemia type I (HT1) is a rare autosomal recessive metabolic disorder caused by fumarylacetoacetate hydrolase deficiency. Delayed diagnosis may result in progressive liver disease, cirrhosis, and liver failure requiring transplantation. We report a child with HT1 diagnosed only after liver transplantation.
Case presentation. A male infant, born at term without significant perinatal complications, presented at 4 months of age with abdominal distension and hepatosplenomegaly. Imaging studies revealed multiple intrahepatic cystic lesions and biliary abnormalities suggestive of Caroli disease and chronic cholangiopathy. Despite extensive investigations, the etiology remained unclear while progressive hepatic dysfunction, portal hypertension, and advanced cirrhosis developed. Metabolic evaluation performed during pre-transplant assessment demonstrated markedly elevated urinary succinylacetone, 4-hydroxyphenyllactic acid, and 4-hydroxyphenylpyruvic acid levels, strongly suggestive of HT1. However, the diagnosis was established only after living-donor liver transplantation.
The absence of neonatal metabolic screening and limited access to specialized diagnostic testing contributed to significant diagnostic delay. Consequently, nitisinone therapy and dietary restriction of tyrosine and phenylalanine were not initiated before irreversible liver damage occurred. Following transplantation, disease-specific nutritional management and multidisciplinary follow-up became essential components of care.
Conclusions. HT1 should be considered in infants presenting with unexplained hepatosplenomegaly and progressive liver disease. Early metabolic screening, particularly urinary succinylacetone measurement, is essential for timely diagnosis and initiation of specific treatment, potentially preventing progression to end-stage liver disease and liver transplantation.
Keywords: hereditary tyrosinemia type I, liver failure, liver transplantation, succinylacetone, nutritional management.
